Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2014
05/27/2014CA2575214C Substituted triazines as prion protein ligands and their use to detect or remove prions
05/27/2014CA2568835C Quinazolinone derivatives as parp inhibitors
05/27/2014CA2568750C Compositions and methods for treatment of neovascular diseases
05/27/2014CA2552909C Pharmaceuticals for topical application in animals
05/27/2014CA2551696C Immunopotentiator and method of enhancing immunoactivity using the same
05/27/2014CA2549898C Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
05/27/2014CA2548374C Pyrazole derivatives as protein kinase modulators
05/27/2014CA2547053C Compositions and methods for treatment of cardiovascular disorders and diseases
05/27/2014CA2542996C Immunemodulating oligosaccharides
05/27/2014CA2540272C Preventive or ameliorating agent for liver diseases associated with hepatopathy
05/27/2014CA2521220C Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains
05/27/2014CA2497552C Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
05/27/2014CA2457799C Method and quantification assay for determining c-kit/scf/pakt status
05/27/2014CA2442080C A preparation for restenosis prevention
05/27/2014CA2440261C Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
05/27/2014CA2375992C Method for controlled production of ultrafine microparticles and nanoparticles
05/27/2014CA2371814C Trpm-2 antisense therapy
05/27/2014CA2298855C Interleukin-18 binding proteins, their preparation and use
05/22/2014WO2014078868A1 Methods of treatment of keratinocyte-derived lesions
05/22/2014WO2014078857A1 Ergoline derivatives as dopamine receptor modulators
05/22/2014WO2014078842A1 Deuterated cftr potentiators
05/22/2014WO2014078832A1 Implantable drug delivery compositions and methods of treatment thereof
05/22/2014WO2014078813A1 Compounds and compositions for the treatment of parasitic diseases
05/22/2014WO2014078802A1 Compounds and compositions for the treatment of parasitic diseases
05/22/2014WO2014078801A1 Methods and compositions comprising guanidines for treating biofilms
05/22/2014WO2014078778A2 Antiviral azasugar-containing nucleosides
05/22/2014WO2014078766A1 Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
05/22/2014WO2014078686A1 Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
05/22/2014WO2014078655A1 Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
05/22/2014WO2014078645A1 Heterocyclic glutaminase inhibitors
05/22/2014WO2014078637A1 Novel heterocyclic derivatives as modulators of kinase activity
05/22/2014WO2014078634A1 Novel imidazol-piperidinyl derivatives as modulators of kinase activity
05/22/2014WO2014078633A1 Methods for treating cancers having brca2 and palb2 mutations
05/22/2014WO2014078622A1 Method and system for diagnosing and treating preeclampsia
05/22/2014WO2014078611A1 Dihydropyrazole gpr40 modulators
05/22/2014WO2014078610A1 Dihydropyrazole gpr40 modulators
05/22/2014WO2014078609A1 Pyrrolidine gpr40 modulators
05/22/2014WO2014078608A1 Dihydropyrazole gpr40 modulators
05/22/2014WO2014078578A1 Pyrrolopyrimidine compounds as kinase inhibitors
05/22/2014WO2014078576A2 Oral transmucosal drug delivery system
05/22/2014WO2014078575A2 Novel orally bioavailable breathing control modulating compounds, and methods of using same
05/22/2014WO2014078568A1 Methods and compositions for treating schizophrenia
05/22/2014WO2014078486A1 Sustained-release dosage forms of ruxolitinib
05/22/2014WO2014078484A1 Conjugates for treating diseases caused by psma expressing cells
05/22/2014WO2014078479A2 INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
05/22/2014WO2014078463A1 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
05/22/2014WO2014078459A1 Compositions and methods for increasing energy metabolism
05/22/2014WO2014078454A1 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
05/22/2014WO2014078447A1 Calcium flux agonists and methods therefor
05/22/2014WO2014078446A2 Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
05/22/2014WO2014078436A1 D-alanine ester of sp-nucleoside analog
05/22/2014WO2014078435A1 Compositions containing a biologically active material and a non-ordered inorganic oxide
05/22/2014WO2014078434A1 Compounds and methods for skin repair
05/22/2014WO2014078427A1 D-alanine ester of rp-nucleoside analog
05/22/2014WO2014078417A1 Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078408A1 Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078394A1 Method of treatment of aggression
05/22/2014WO2014078383A1 Inhibition of drug resistant cancer cells
05/22/2014WO2014078378A1 Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078377A1 Methods and compositions for treating schizophrenia
05/22/2014WO2014078372A1 Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078350A1 Methods of treating patients infected with hiv and htlv
05/22/2014WO2014078331A1 N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078328A1 N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078325A1 N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078323A1 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
05/22/2014WO2014078314A1 Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
05/22/2014WO2014078309A1 Cannabinoid receptor mediating compounds
05/22/2014WO2014078295A1 Gemcitabine prodrugs and uses thereof
05/22/2014WO2014078294A1 Indole compounds and their use as antimicrobials
05/22/2014WO2014078257A1 Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
05/22/2014WO2014078220A1 Secondary alcohol subsituted triazoles as pde10 inhibitors
05/22/2014WO2014078217A1 Cyclopropyl imidazopyridine pde10 inhibitors
05/22/2014WO2014078216A1 Cyclobutyl benzimidazoles as pde10 inhibitors
05/22/2014WO2014078214A1 Azetidine benzimidazoles as pde10 inhibitors
05/22/2014WO2014078211A1 Heteroaromatic compounds as pi3 kinase modulators and methods of use
05/22/2014WO2014078209A1 Aryl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
05/22/2014WO2014078208A1 Aryl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
05/22/2014WO2014078206A1 Allene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
05/22/2014WO2014078200A1 2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
05/22/2014WO2014078197A1 2-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators
05/22/2014WO2014078162A1 Ectoparasiticidal methods and formulations
05/22/2014WO2014078059A1 Methods for the treatment of sialorrhea
05/22/2014WO2014077915A1 Methods and materials for identifying malignant skin lesions
05/22/2014WO2014077787A1 Combinations including abeta2 agonist and glycopyrrolate
05/22/2014WO2014077784A1 Method of treating cancer
05/22/2014WO2014077723A1 Method for obtaining a probiotic preparation of particulate antigens of corynebacteria, probiotic bacterial preparation for preventing and treating tuberculosis, and symbiotic strain
05/22/2014WO2014077715A1 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
05/22/2014WO2014077712A1 Solid lipid nanoparticles of roxithromycin for hair loss or acne
05/22/2014WO2014077668A1 Combination of molecular iodine and anthracyclines for human use for the prevention and treatment of iodine-capturing chemically-resistant cancers
05/22/2014WO2014077666A1 Composition of excipients and pharmaceutical forms with sustained release and increased bioavailability of antibacterial drugs, anticoccidial drugs and other drugs for commercial poultry and pigs
05/22/2014WO2014077655A1 Sustained-release polymer microsphere containing anastrozole
05/22/2014WO2014077621A1 Composition for preventing hair loss and accelerating hair growth
05/22/2014WO2014077570A1 Composition for preventing or treating inflammation
05/22/2014WO2014077532A1 Novel piperazine derivative, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating metabolic disorders
05/22/2014WO2014077476A1 Method for preparing β-glucan
05/22/2014WO2014077409A1 Agent for mitigating side effect of sunitinib
05/22/2014WO2014077401A1 Nitrogen-containing heterocyclic compound
05/22/2014WO2014077383A1 Agent for ameliorating allergy
05/22/2014WO2014077358A1 Radiation exposure treatment agent and radiation exposure treatment method
1 ... 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 ... 7860